Kamada(KMDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KMDA Kamada

Market Closed 12-12 16:00:00 EST

7.02

+0.00

0.00%

盘后7.02

+0.000.00%

16:10 EST

High7.09	Low6.94	Vol79.75K
Open6.99	D1 Closing7.02	Amplitude2.08%
Mkt Cap404.92M	Tradable Cap65.71M	Total Shares57.68M
T/O560.46K	T/O Rate0.85%	Tradable Shares9.36M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KMDA","market":"US","secType":"STK","nameCN":"Kamada","latestPrice":7.02,"timestamp":1765573200000,"preClose":7.02,"halted":0,"volume":79750,"hourTrading":{"tag":"盘后","latestPrice":7.02,"preClose":7.02,"latestTime":"16:10 EST","volume":7,"amount":49.14,"timestamp":1765573804028},"delay":0,"floatShares":9360967,"shares":57681590,"eps":0.3496,"marketStatus":"Market Closed","change":0,"latestTime":"12-12 16:00:00 EST","open":6.99,"high":7.0858,"low":6.94,"amount":560458.8231,"amplitude":0.020769,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.3496,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1369972800000,"exchange":"NASDAQ","adjPreClose":7.02,"postHourTrading":{"tag":"盘后","latestPrice":7.02,"preClose":7.02,"latestTime":"16:10 EST","volume":7,"amount":49.14,"timestamp":1765573804028},"volumeRatio":0.38684935353075794,"impliedVol":0.6459,"impliedVolPercentile":0.232},"requestUrl":"/m/hq/s/KMDA","defaultTab":"news","newsList":[{"id":"2590377343","title":"Kamada Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2590377343","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590377343?lang=en_us&edition=fundamental","pubTime":"2025-12-09 19:51","pubTimestamp":1765281060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KMDA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2025 06:51 ET (11:51 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KMDA"],"gpt_icon":0},{"id":"2589358437","title":"Kamada to Discontinue Phase 3 Trial of Inhaled AAT: Shares Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2589358437","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589358437?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:50","pubTimestamp":1765198200,"startTime":"0","endTime":"0","summary":"Kamada (KMDA) said Monday that it will discontinue the phase 3 trial of inhaled AAT for the treatment of Alpha-1 Antitrypsin Deficiency, or AATD, due to the \"low likelihood of a successful efficacy ou","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AAT","BK4160","KMDA","BK4139"],"gpt_icon":0},{"id":"2589048337","title":"Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2589048337","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589048337?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:00","pubTimestamp":1765195200,"startTime":"0","endTime":"0","summary":"Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically Significant Benefit in its Primary EndpointKamada Continues to Supply GLASS","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201409/0/en/Kamada-Announces-Discontinuation-of-its-Phase-3-Inhaled-AAT-Clinical-Trial-Reiterates-2025-Full-Year-Guidance-and-Projects-Double-Digit-Growth-in-Revenues-and-Profitability-in-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAT","KMDA"],"gpt_icon":0},{"id":"2589033790","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 06:55 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2589033790","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589033790?lang=en_us&edition=fundamental","pubTime":"2025-12-08 19:55","pubTimestamp":1765194900,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 06:55 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nAQN2LCGKV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KMDA","BK4139"],"gpt_icon":0},{"id":"2588269058","title":"Kamada Ltd. Amends Shareholder Meeting Notice and Voting Procedures","url":"https://stock-news.laohu8.com/highlight/detail?id=2588269058","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588269058?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:40","pubTimestamp":1764679223,"startTime":"0","endTime":"0","summary":"Kamada Ltd. has issued an amendment to its previously filed proxy statement for the upcoming Annual General Meeting of Shareholders scheduled for December 10, 2025. The amendment addresses comments from EMDA, an Israeli proxy advisor, and updates the company's Articles of Association to align with current practices and applicable law, including changes to meeting notice requirements, succession procedures for meeting chairmanship, voting procedures, and provisions for urgent Board meetings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kamada Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commissi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL8Hj6hS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KMDA","BK4139"],"gpt_icon":0},{"id":"2582395149","title":"Kamada’s Growth Potential and Strategic Development Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2582395149","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582395149?lang=en_us&edition=fundamental","pubTime":"2025-11-12 00:45","pubTimestamp":1762879528,"startTime":"0","endTime":"0","summary":"Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Kamada, retaining the price target of $11.00. Andrew Fein has given his Buy ratin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/kamadas-growth-potential-and-strategic-development-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/kamadas-growth-potential-and-strategic-development-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KMDA"],"gpt_icon":0},{"id":"2582602339","title":"Kamada Ltd. Reports Strong Financial Growth in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2582602339","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582602339?lang=en_us&edition=fundamental","pubTime":"2025-11-11 12:15","pubTimestamp":1762834549,"startTime":"0","endTime":"0","summary":"Kamada Ltd ( ($KMDA) ) has released its Q3 earnings. Here is a breakdown of the information Kamada Ltd presented to its investors. Kamada Ltd. is a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kamada-ltd-reports-strong-financial-growth-in-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kamada-ltd-reports-strong-financial-growth-in-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KMDA"],"gpt_icon":0},{"id":"2582384621","title":"Kamada Ltd. Reports Strong Growth Amid Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2582384621","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582384621?lang=en_us&edition=fundamental","pubTime":"2025-11-11 08:14","pubTimestamp":1762820062,"startTime":"0","endTime":"0","summary":"Kamada Ltd (($IL:KMDA)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call for Kamada Ltd. painte...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kamada-ltd-reports-strong-growth-amid-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kamada-ltd-reports-strong-growth-amid-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KMDA"],"gpt_icon":0},{"id":"1160126233","title":"Kamada Q3 2025 Earnings Call Summary and Q&A Highlights: Strong Revenue Growth and Strategic Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=1160126233","media":"Earnings Call","labels":["earningsCall"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160126233?lang=en_us&edition=fundamental","pubTime":"2025-11-10 22:15","pubTimestamp":1762784157,"startTime":"0","endTime":"0","summary":"[Management View]Total revenues reached $47 million in Q3, a 13% increase YoY. Gross profit was $19.8 million with a margin of 42%. Net income was $5.3 million, up 37% YoY. Adjusted EBITDA was $11.7...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"earningsCall","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KMDA"],"gpt_icon":0},{"id":"2582872161","title":"Kamada (KMDA) Q3 2025 Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2582872161","media":"Motley Fool Transcribing","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582872161?lang=en_us&edition=fundamental","pubTime":"2025-11-10 22:13","pubTimestamp":1762783991,"startTime":"0","endTime":"0","summary":"DATEMonday, Nov. 10, 2025 at 8:30 a.m. ETCALL PARTICIPANTSChief Executive Officer — Amir LondonChief Financial Officer — Chaime OrlevOperator[Moderator] — Brian RitchieNeed a quote from a Motley Fool analyst?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_motley_transcript","url":"https://www.fool.com/earnings/call-transcripts/2025/11/10/kamada-kmda-q3-2025-earnings-call-transcript/","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/earnings/call-transcripts/2025/11/10/kamada-kmda-q3-2025-earnings-call-transcript/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_motley_transcript","symbols":["KMDA"],"gpt_icon":0},{"id":"2582875915","title":"Kamada sees FY25 revenue $178M-$182M","url":"https://stock-news.laohu8.com/highlight/detail?id=2582875915","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582875915?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:18","pubTimestamp":1762777087,"startTime":"0","endTime":"0","summary":"Kamada (KMDA) is reiterating its annual financial guidance comprising of 2025 total revenues in the range of $178 million to $182 million and adjus...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kamada-sees-fy25-revenue-178m-182m-thefly-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kamada-sees-fy25-revenue-178m-182m-thefly-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KMDA"],"gpt_icon":0},{"id":"2582028873","title":"Kamada Q3 EPS $0.09 Misses $0.10 Estimate, Sales $47.010M Beat $45.811M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582028873","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582028873?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:11","pubTimestamp":1762776707,"startTime":"0","endTime":"0","summary":"Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.10 by 7.22 percent. This is a 28.57 percent increase over earnings of $0.07 per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48748352/kamada-q3-eps-0-09-misses-0-10-estimate-sales-47-010m-beat-45-811m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KMDA"],"gpt_icon":0},{"id":"2582873077","title":"Biopharma firm Kamada's Q3 revenue up 13%, beats estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2582873077","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582873077?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:10","pubTimestamp":1762776625,"startTime":"0","endTime":"0","summary":"Biopharma firm Kamada's Q3 revenue up 13%, beats estimatesOverviewKamada Q3 revenue rises 13% to $47 mln, beating analyst expectationsAdjusted EBITDA for Q3 increases 34% yr/yr, reflecting strong oper","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM0DT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KMDA"],"gpt_icon":0},{"id":"2582873124","title":"Press Release: Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2582873124","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582873124?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:00","pubTimestamp":1762776000,"startTime":"0","endTime":"0","summary":"-- Third Quarter Revenues of $47.0 Million, up 13% Year-over-Year, and. Adjusted EBITDA of $11.7 Million, up 34% Year-Over Year. -- Nine Month Revenue of $135.8 Million, up 11% Year-over-Year; Adjusted. -- Positive Outlook for Remainder of 2025 Based on the Company's Diverse. Product Portfolio Supports Full-Year Revenue Guidance of $178. Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million. of 2025; as of September 30, 2025, had $72.0 Million of Available Cash. \"We have consistently demonstrated our ability to convert profitability to operational cash flow, as we generated $17.9 million of cash from operating activities during the first nine months of the year, contributing to our strong cash position as of the end of the quarter of $72.0 million. As we advance our business development initiatives, we plan to leverage our financial strength to enrich our portfolio of marketed products and support our continued long-term annual double-digit profitable growth,\" added Mr. L","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","KMDA","EMA","BK4139","R","BK4081","BK4232"],"gpt_icon":0},{"id":"2581848678","title":"Kamada Ltd  expected to post earnings of 9 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581848678","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581848678?lang=en_us&edition=fundamental","pubTime":"2025-11-07 23:05","pubTimestamp":1762527906,"startTime":"0","endTime":"0","summary":"Kamada Ltd  expected to post earnings of9cents a share - Earnings Preview Kamada Ltd KMDA.OQ, KMDA.O is expected to  show a rise in quarterly revenue when it reports  results on November 10 for the pe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ230:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KMDA"],"gpt_icon":0},{"id":"2580947739","title":"Kamada Initiates Clinical Trial for CYTOGAM in Kidney Transplantation","url":"https://stock-news.laohu8.com/highlight/detail?id=2580947739","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580947739?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:29","pubTimestamp":1762259359,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Kamada ( ($IL:KMDA) ). Kamada Ltd. announced the enrollment of the first patient in a clinical trial for CYTOGA...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kamada-initiates-clinical-trial-for-cytogam-in-kidney-transplantation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kamada-initiates-clinical-trial-for-cytogam-in-kidney-transplantation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KMDA","BK4139"],"gpt_icon":0},{"id":"2580373558","title":"Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation","url":"https://stock-news.laohu8.com/highlight/detail?id=2580373558","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580373558?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:00","pubTimestamp":1762257600,"startTime":"0","endTime":"0","summary":"Post Marketing Study to Evaluate the Role of CYTOGAM in the Reduction of Risk of Late CMV Disease Following the Conclusion of Standardly Prescribed Antiviral Treatment in High-Risk Kidney Transplant R","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3180130/0/en/Kamada-Announces-First-Patient-Enrolled-into-an-Investigator-Initiated-Clinical-Trial-of-CYTOGAM-to-Prevent-Cytomegalovirus-in-Kidney-Transplantation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KMDA","IE00B3T34201.USD","IE00BD4GTW91.USD","IE00BD4GTV84.USD","BK4139","BK4585","LU0006061336.USD","IE00BMG7P702.HKD","IE00BMQBXF63.USD","D","IE00BZ18W456.USD","IE00BMG7P819.SGD","BK4588","IE00BMG7P694.USD","IE00B29SXK94.USD","IE00BD4GTT62.SGD","BK4208","IE00BMG7P926.USD","IE00BMG7P587.USD","IE00BZ18W340.USD","IE00B29SXL02.USD","BK4566"],"gpt_icon":0},{"id":"2580297645","title":"Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2580297645","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580297645?lang=en_us&edition=fundamental","pubTime":"2025-11-03 20:00","pubTimestamp":1762171200,"startTime":"0","endTime":"0","summary":"Company to Host Conference Call at 8:30am ETREHOVOT, Israel and HOBOKEN, N.J., Nov.  03, 2025  (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/03/3179048/0/en/Kamada-to-Announce-Third-Quarter-and-Nine-Months-Ended-September-30-2025-Financial-Results-on-November-10-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B29SXK94.USD","BK4585","BK4588","BK4139","KMDA","D","IE00BZ18W340.USD","BK4208","IE00BD4GTT62.SGD","IE00B29SXL02.USD","IE00B3T34201.USD","IE00BD4GTW91.USD","BK4566","IE00BMQBXF63.USD","IE00BMG7P694.USD","IE00BD4GTV84.USD","IE00BMG7P819.SGD","LU0006061336.USD","IE00BZ18W456.USD","IE00BMG7P702.HKD","IE00BMG7P926.USD","IE00BMG7P587.USD"],"gpt_icon":0},{"id":"2579977955","title":"Kamada to Present at the Stifel 2025 Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2579977955","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579977955?lang=en_us&edition=fundamental","pubTime":"2025-10-29 19:00","pubTimestamp":1761735600,"startTime":"0","endTime":"0","summary":"REHOVOT, Israel and Hoboken, N.J., Oct.  29, 2025  (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/29/3176285/0/en/Kamada-to-Present-at-the-Stifel-2025-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ18W456.USD","IE00BMG7P587.USD","LU0128526141.USD","BK4127","IE00BMQBXF63.USD","LU0029874061.USD","SF","D","IE00B29SXL02.USD","IE00BD4GTT62.SGD","BK4581","BK4585","IE00BMG7P926.USD","IE00BD4GTV84.USD","IE00BZ18W340.USD","IE00B3T34201.USD","LABU","XBI","BK4137","BK4139","XLV","BK4566","IE00BD4GTW91.USD","IE00BMG7P702.HKD","HCSG","LU0006061336.USD","IE00BMG7P694.USD","BK4588","IE00BMG7P819.SGD","KMDA","BK4208","IE00B29SXK94.USD"],"gpt_icon":0},{"id":"2577303426","title":"Kamada Ltd. Announces Date for Annual General Meeting of Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2577303426","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577303426?lang=en_us&edition=fundamental","pubTime":"2025-10-23 19:03","pubTimestamp":1761217405,"startTime":"0","endTime":"0","summary":"Kamada Ltd. has announced that its Annual General Meeting of Shareholders will be held on December 10, 2025, at the company's offices in Rehovot, Israel. Shareholders will be asked to vote on the re-election of seven directors to serve until the next annual general meeting and until their respective successors are duly elected. In addition, the meeting will include a proposal to approve the grant of options to Amir London, the company's Chief Executive Officer, as well as the adoption of an amended and restated Compensation Policy for Executive Officers and Directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kamada Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analy","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nNDL6kdjh4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KMDA","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kamada.com","stockEarnings":[{"period":"1week","weight":-0.0085},{"period":"1month","weight":-0.0357},{"period":"3month","weight":0},{"period":"6month","weight":0.0203},{"period":"1year","weight":0.2124},{"period":"ytd","weight":0.1527}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. It has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. Kamada Ltd. was incorporated in 1990 and is headquartered in Rehovot, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.032452},{"month":2,"riseRate":0.5,"avgChangeRate":0.023525},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.032342},{"month":4,"riseRate":0.5,"avgChangeRate":0.01859},{"month":5,"riseRate":0.5,"avgChangeRate":-0.040831},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.009703},{"month":7,"riseRate":0.615385,"avgChangeRate":0.027735},{"month":8,"riseRate":0.461538,"avgChangeRate":0.022381},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.037187},{"month":10,"riseRate":0.461538,"avgChangeRate":-0.010373},{"month":11,"riseRate":0.538462,"avgChangeRate":0.029323},{"month":12,"riseRate":0.461538,"avgChangeRate":0.020719}],"exchange":"NASDAQ","name":"Kamada","nameEN":"Kamada"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kamada(KMDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kamada(KMDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kamada,KMDA,Kamada股票,Kamada股票老虎,Kamada股票老虎国际,Kamada行情,Kamada股票行情,Kamada股价,Kamada股市,Kamada股票价格,Kamada股票交易,Kamada股票购买,Kamada股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kamada(KMDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kamada(KMDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}